Page last updated: 2024-11-05

ethoxyacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID12301
CHEMBL ID1159929
CHEBI ID173365
SCHEMBL ID48574
MeSH IDM0105297

Synonyms (54)

Synonym
unii-467vw095bx
acetic acid, 2-ethoxy-
467vw095bx ,
CHEBI:173365
2-ethoxy-acetic acid
acetic acid, ethoxy-
nsc6750
627-03-2
nsc-6750
2-ethoxyacetic acid
ethoxyacetic acid
NCGC00090711-01
ai3-24145
nsc 6750
einecs 210-978-2
ethoxy acetic acid
ethoxyacetic acid (egmee (110-80-5))
brn 1743037
ccris 7194
ethoxyacetic acid, 98%
inchi=1/c4h8o3/c1-2-7-3-4(5)6/h2-3h2,1h3,(h,5,6)
yzgqdnoigfbykf-uhfffaoysa-
E0377
ethoxy-acetic acid anion
CHEMBL1159929
AKOS000120246
A833937
NCGC00090711-02
dtxsid7031294 ,
dtxcid5011294
tox21_303384
NCGC00257362-01
cas-627-03-2
NCGC00259980-01
tox21_202431
STL166132
FT-0625741
o-ethylglycolic acid
SCHEMBL48574
ethoxy-acetic acid
F2191-0091
mfcd00004310
ethoxyacetic acid, purum, >=98.0% (gc)
glycolic acid ethyl ether
CS-0071579
Q26841235
EN300-21303
STR05191
AMY4062
D73862
HY-W027555
2-ethoxyaceticacid
?ethoxyacetic acid
Z104495232

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" When animals were pretreated with inhibitors of alcohol metabolism followed by a testicular toxic dose of EGME (500 mg/kg), an inhibitor of alcohol dehydrogenase (pyrazole) offered complete protection."( Testicular toxicity produced by ethylene glycol monomethyl and monoethyl ethers in the rat.
Creasy, DM; Foster, JR; Foster, PM; Gray, TJ, 1984
)
0.27
" Based on toxicity information for EGME and related chemicals and accompanied by adverse outcome pathway information on the testicular toxicity of EGME, this category was defined as chemicals that are metabolized to methoxy- or ethoxyacetic acid, a substance responsible for testicular toxicity."( Development of a category approach to predict the testicular toxicity of chemical substances structurally related to ethylene glycol methyl ether.
Hasegawa, R; Hayashi, M; Hirose, A; Ono, A; Sakuratani, Y; Tanaka, Y; Yamada, T; Yamazoe, Y, 2014
)
0.59

Bioavailability

ExcerptReferenceRelevance
" The results show that glycol ethers are very well absorbed through the skin."( Occupational chronic exposure to organic solvents. XIV. Examinations concerning the evaluation of a limit value for 2-ethoxyethanol and 2-ethoxyethyl acetate and the genotoxic effects of these glycol ethers.
Angerer, J; Letzel, S; Rüdiger, HW; Söhnlein, B; Weltle, D, 1993
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Urinary excretion of ethoxyacetic acid (EAA) and its glycine conjugate was followed up to 60 h after dosing and compared to data of experimentally exposed human volunteers."( Comparative urinary excretion of ethoxyacetic acid in man and rat after single low doses of ethylene glycol monoethyl ether.
Groeseneken, D; Masschelein, R; Van Vlem, E; Veulemans, H, 1988
)
0.87
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carboxylic acidA carbon oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency36.38830.002541.796015,848.9004AID1347395
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency27.91810.000657.913322,387.1992AID1259394
estrogen nuclear receptor alphaHomo sapiens (human)Potency25.30110.000229.305416,493.5996AID743075; AID743079
Nuclear receptor ROR-gammaHomo sapiens (human)Potency0.59560.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID167125Eye irritation potential accessed using Draize in vivo rabbit eye irritation test2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (43.24)18.7374
1990's10 (27.03)18.2507
2000's5 (13.51)29.6817
2010's6 (16.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.18 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index32.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]